116 
HR 6344 RDS
shall include an evaluation of the likely human health and 
environmental impacts of mycoherbicides derived from 
fungus naturally existing in the soil. 
(b) STUDY.—The study required by this section shall 
be conducted in United States territory and not in any 
foreign country. 
SEC. 1112. REQUIREMENT FOR STUDY OF STATE PRE-
CURSOR CHEMICAL CONTROL LAWS. 
(a) STUDY.—The Director of National Drug Control 
Policy, in consultation with the National Alliance for 
Model State Drug Laws, shall conduct a study of State 
laws with respect to precursor chemical controls. 
(b) REPORT.—Not later than 6 months after the date 
of the enactment of this Act, the Director of National 
Drug Control Policy shall submit a report to Congress on 
the results of the study under subsection (a), including— 
(1) a comparison of the State laws studied and 
the effectiveness of each such law; and 
(2) a list of best practices observed with respect 
to such laws. 
SEC. 1113. REQUIREMENT FOR STUDY OF DRUG ENDAN-
GERED CHILDREN PROGRAMS. 
(a) STUDY.—The Director of National Drug Control 
Policy shall conduct a study of methamphetamine-related 
VerDate Aug 31 2005 
23:24 Dec 12, 2006
Jkt 059200
PO 00000
Frm 00116
Fmt 6652
Sfmt 6201
E:\BILLS\H6344.RDS
H6344
pwalker on PRODPC60 with BILLS
117 
HR 6344 RDS
activities that are conducted by different Drug Endan-
gered Children programs administered by States. 
(b) REPORT.—Not later than 6 months after the date 
of the enactment of this Act, the Director of National 
Drug Control Policy shall submit to Congress a report on 
the results of the study under subsection (a). Such report 
shall include— 
(1) an analysis of the best practices of the ac-
tivities studied; and 
(2) recommendations for establishing a national 
policy to address drug endangered children, based on 
the Drug Endangered Children programs adminis-
tered by States. 
(c) DEFINITIONS.—In this section— 
(1) the term ‘‘methamphetamine-related activ-
ity’’ means any activity related to the production, 
use, or effects of methamphetamine; and 
(2) the term ‘‘drug endangered children’’ means 
children whose physical, mental, or emotional health 
are at risk because of the production, use, or effects 
of methamphetamine by another person. 
SEC. 1114. STUDY ON DRUG COURT HEARINGS IN NON-
TRADITIONAL PLACES. 
(a) FINDING.—Congress finds that encouraging drug 
courts and schools to enter into partnerships that allow 
VerDate Aug 31 2005 
23:24 Dec 12, 2006
Jkt 059200
PO 00000
Frm 00117
Fmt 6652
Sfmt 6201
E:\BILLS\H6344.RDS
H6344
pwalker on PRODPC60 with BILLS
118 
HR 6344 RDS
students to see the repercussions of drug abuse by non- 
violent offenders may serve as a strong deterrent and pro-
mote demand reduction. 
(b) STUDY.—The Director of the Office of National 
Drug Control Policy shall conduct a study on drug court 
programs that conduct hearings in nontraditional public 
places, such as schools. At a minimum, the study shall 
evaluate similar programs in operation, such as the pro-
gram operated in the Fourth Judicial District Drug 
Court, in Washington County, Arkansas. 
(c) REQUIREMENT.—At the same time the President 
submits to Congress the National Drug Control Strategy 
due February 1, 2007, pursuant to section 706 of the Of-
fice of National Drug Control Policy Reauthorization Act 
of 1998, the President shall submit to Congress a report 
on the study conducted under subsection (b). The report 
shall include an evaluation of the results of the study and 
such recommendations as the President considers appro-
priate. 
(d) DEMAND REDUCTION.—In this section, the term 
‘‘demand reduction’’ has the meaning provided in section 
702(1) of the Office of National Drug Control Policy Re-
authorization Act of 1998 (21 U.S.C. 1701(1)). 
VerDate Aug 31 2005 
23:24 Dec 12, 2006
Jkt 059200
PO 00000
Frm 00118
Fmt 6652
Sfmt 6201
E:\BILLS\H6344.RDS
H6344
pwalker on PRODPC60 with BILLS
119 
HR 6344 RDS
SEC. 1115. REPORT ON TRIBAL GOVERNMENT PARTICIPA-
TION IN HIDTA PROCESS. 
(a) REPORT REQUIREMENT.—The Director of the 
Office of National Drug Control Policy shall prepare a re-
port for Congress on the representation of tribal govern-
ments in the High Intensity Drug Trafficking Areas Pro-
gram and in high intensity drug trafficking areas des-
ignated under that Program. The report shall include— 
(1) a list of the tribal governments represented 
in the Program and a description of the participa-
tion by such governments in the Program; 
(2) an explanation of the rationale for the level 
of representation by such governments; and 
(3) recommendations by the Director for meth-
ods for increasing the number of tribal governments 
represented in the Program. 
(b) DEADLINE.—The report prepared under sub-
section (a) shall be submitted not later than 1 year after 
the date of the enactment of this Act. 
(c) DEFINITION.—In this section, the term ‘‘High In-
tensity Drug Trafficking Areas Program’’ means the pro-
gram established under section 707 of the Office of Na-
tional Drug Control Policy Reauthorization Act of 1998 
(21 U.S.C. 1706) 
VerDate Aug 31 2005 
23:24 Dec 12, 2006
Jkt 059200
PO 00000
Frm 00119
Fmt 6652
Sfmt 6201
E:\BILLS\H6344.RDS
H6344
pwalker on PRODPC60 with BILLS
120 
HR 6344 RDS
SEC. 1116. REPORT ON SCHOOL DRUG TESTING. 
(a) REPORT REQUIREMENT.—The Director of Na-
tional Drug Control Policy shall prepare a report on drug 
testing in schools. The report shall include a list of sec-
ondary schools that have initiated drug testing from 
among those schools that have attended conferences on 
drug testing sponsored by the Office of National Drug 
Control Policy. 
(b) DEADLINE.—Not later than 120 days after the 
date of the enactment of this Act, the Director of National 
Drug Control Policy shall submit to Congress the report 
required under subsection (a). 
SEC. 1117. REPORT ON ONDCP PERFORMANCE BONUSES. 
(a) REPORT REQUIREMENT.—The Director of Na-
tional Drug Control Policy shall prepare a report on per-
formance bonuses at the Office of National Drug Control 
Policy. The report shall include a list of employees who 
received performance bonuses, and the amount of such bo-
nuses, for the period beginning on October 1, 2004, and 
ending on the date of submission of the report. 
(b) DEADLINE.—Not later than 120 days after the 
date of the enactment of this Act, the Director of National 
Drug Control Policy shall submit to Congress the report 
required under subsection (a). 
VerDate Aug 31 2005 
23:24 Dec 12, 2006
Jkt 059200
PO 00000
Frm 00120
Fmt 6652
Sfmt 6201
E:\BILLS\H6344.RDS
H6344
pwalker on PRODPC60 with BILLS
121 
HR 6344 RDS
SEC. 1118. REQUIREMENT FOR DISCLOSURE OF FEDERAL 
SPONSORSHIP 
OF 
ALL 
FEDERAL 
ADVER-
TISING OR OTHER COMMUNICATION MATE-
RIALS. 
Section 712 is amended to read as follows: 
‘‘SEC. 712. REQUIREMENT FOR DISCLOSURE OF FEDERAL 
SPONSORSHIP 
OF 
ALL 
FEDERAL 
ADVER-
TISING OR OTHER COMMUNICATION MATE-
RIALS. 
‘‘(a) REQUIREMENT.—Each advertisement or other 
communication paid for by the Office, either directly or 
through a contract awarded by the Office, shall include 
a prominent notice informing the target audience that the 
advertisement or other communication is paid for by the 
Office. 
‘‘(b) ADVERTISEMENT
OR
OTHER
COMMUNICA-
TION.—In this section, the term ‘advertisement or other 
communication’ includes— 
‘‘(1) an advertisement disseminated in any 
form, including print or by any electronic means; 
and 
‘‘(2) a communication by an individual in any 
form, including speech, print, or by any electronic 
means.’’. 
VerDate Aug 31 2005 
23:24 Dec 12, 2006
Jkt 059200
PO 00000
Frm 00121
Fmt 6652
Sfmt 6201
E:\BILLS\H6344.RDS
H6344
pwalker on PRODPC60 with BILLS
122 
HR 6344 RDS
SEC. 1119. AWARDS FOR DEMONSTRATION PROGRAMS BY 
LOCAL PARTNERSHIPS TO COERCE ABSTI-
NENCE 
IN 
CHRONIC 
HARD-DRUG 
USERS 
UNDER COMMUNITY SUPERVISION THROUGH 
THE USE OF DRUG TESTING AND SANCTIONS. 
At the end of the Act, insert the following: 
‘‘SEC. 716. AWARDS FOR DEMONSTRATION PROGRAMS BY 
LOCAL PARTNERSHIPS TO COERCE ABSTI-
NENCE 
IN 
CHRONIC 
HARD-DRUG 
USERS 
UNDER COMMUNITY SUPERVISION THROUGH 
THE USE OF DRUG TESTING AND SANCTIONS. 
‘‘(a) AWARDS REQUIRED.—The Director shall make 
competitive awards to fund demonstration programs by el-
igible partnerships for the purpose of reducing the use of 
illicit drugs by chronic hard-drug users living in the com-
munity while under the supervision of the criminal justice 
system. 
‘‘(b) USE OF AWARD AMOUNTS.—Award amounts re-
ceived under this section shall be used— 
‘‘(1) to support the efforts of the agencies, or-
ganizations, and researchers included in the eligible 
partnership; 
‘‘(2) to develop and field a drug testing and 
graduated sanctions program for chronic hard-drug 
users living in the community under criminal justice 
supervision; and 
VerDate Aug 31 2005 
23:24 Dec 12, 2006
Jkt 059200
PO 00000
Frm 00122
Fmt 6652
Sfmt 6201
E:\BILLS\H6344.RDS
H6344
pwalker on PRODPC60 with BILLS
123 
HR 6344 RDS
‘‘(3) to assist individuals described in sub-
section (a) by strengthening rehabilitation efforts 
through such means as job training, drug treatment, 
or other services. 
‘‘(c) ELIGIBLE PARTNERSHIP DEFINED.—In this 
section, the term ‘eligible partnership’ means a working 
group whose application to the Director— 
‘‘(1) identifies the roles played, and certifies the 
involvement of, two or more agencies or organiza-
tions, which may include— 
‘‘(A) State, local, or tribal agencies (such 
as those carrying out police, probation, prosecu-
tion, courts, corrections, parole, or treatment 
functions); 
‘‘(B) Federal agencies (such as the Drug 
Enforcement Agency, the Bureau of Alcohol, 
Tobacco, Firearms, and Explosives, and United 
States Attorney offices); and 
‘‘(C) community-based organizations; 
‘‘(2) includes a qualified researcher; 
‘‘(3) includes a plan for using judicial or other 
criminal justice authority to administer drug tests to 
individuals described in subsection (a) at least twice 
a week, and to swiftly and certainly impose a known 
set of graduated sanctions for non-compliance with 
VerDate Aug 31 2005 
23:24 Dec 12, 2006
Jkt 059200
PO 00000
Frm 00123
Fmt 6652
Sfmt 6201
E:\BILLS\H6344.RDS
H6344
pwalker on PRODPC60 with BILLS
124 
HR 6344 RDS
community-release provisions relating to drug absti-
nence (whether imposed as a pre-trial, probation, or 
parole condition or otherwise); 
‘‘(4) includes a strategy for responding to a 
range of substance use and abuse problems and a 
range of criminal histories; 
‘‘(5) includes a plan for integrating data infra-
structure among the agencies and organizations in-
cluded in the eligible partnership to enable seamless, 
real-time tracking of individuals described in sub-
section (a); 
‘‘(6) includes a plan to monitor and measure 
the progress toward reducing the percentage of the 
population of individuals described in subsection (a) 
who, upon being summoned for a drug test, either 
fail to show up or who test positive for drugs. 
‘‘(d) REPORTS TO CONGRESS.— 
‘‘(1) INTERIM REPORT.—Not later than June 1, 
2009, the Director shall submit to Congress a report 
that identifies the best practices in reducing the use 
of illicit drugs by chronic hard-drug users, including 
the best practices identified through the activities 
funded under this section. 
‘‘(2) FINAL REPORT.—Not later than June 1, 
2010, the Director shall submit to Congress a report 
VerDate Aug 31 2005 
23:24 Dec 12, 2006
Jkt 059200
PO 00000
Frm 00124
Fmt 6652
Sfmt 6201
E:\BILLS\H6344.RDS
H6344
pwalker on PRODPC60 with BILLS
125 
HR 6344 RDS
on the demonstration programs funded under this 
section, including on the matters specified in para-
graph (1). 
‘‘(e) AUTHORIZATION OF APPROPRIATIONS.—There 
is authorized to be appropriated to carry out this section 
$4,900,000 for each of fiscal years 2007 through 2009.’’. 
SEC. 1120. POLICY RELATING TO SYRINGE EXCHANGE PRO-
GRAMS. 
Section 703(a) (21 U.S.C. 1702(a)) is amended by 
adding at the end the following: 
‘‘When developing the national drug control policy, any 
policy of the Director relating to syringe exchange pro-
grams for intravenous drug users shall be based on the 
best available medical and scientific evidence regarding 
their effectiveness in promoting individual health and pre-
venting the spread of infectious disease, and their impact 
on drug addiction and use. In making any policy relating 
to syringe exchange programs, the Director shall consult 
with the National Institutes of Health and the National 
Academy of Sciences.’’. 
Passed the House of Representatives December 7, 
2006. 
Attest: 
KAREN L. HAAS, 
Clerk. 
VerDate Aug 31 2005 
23:24 Dec 12, 2006
Jkt 059200
PO 00000
Frm 00125
Fmt 6652
Sfmt 6201
E:\BILLS\H6344.RDS
H6344
pwalker on PRODPC60 with BILLS